We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00005623
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : March 26, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes.

PURPOSE: Randomized phase III trial to determine the effectiveness of cyproterone acetate in treating patients who have hot flashes following surgical or chemical castration for prostate cancer.

Condition or disease Intervention/treatment Phase
Hot Flashes Prostate Cancer Drug: cyproterone acetate Procedure: quality-of-life assessment Phase 3

Detailed Description:


  • Determine the efficacy of cyproterone acetate in patients with hot flashes following bilateral orchiectomy or medical castration for prostate cancer.
  • Compare the effectiveness of two doses of cyproterone acetate in these patients.
  • Determine the safety of this regimen in these patients.
  • Determine the impact of this regimen on the quality of life of these patients.

OUTLINE: This is a randomized, double-blind, placebo controlled study.

Patients receive one of two doses of oral cyproterone acetate or placebo for 12 weeks, followed by a 6-9 month open label extension period with all patients receiving cyproterone acetate.

Quality of life is assessed.


Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Supportive Care
Official Title: A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients
Study Start Date : December 1999
Study Completion Date : January 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Prostate cancer patients who have undergone bilateral orchiectomy or medical castration (LHRH agonist drugs) and are experiencing hot flashes
  • Hot flashes are defined as:

    • At least 3 to 4 moderate to severe hot flashes per day or 21 per week at baseline
    • Present at least 1 month prior to study



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • Greater than 12 months


  • WBC at least 3,000/uL
  • Platelet count at least 75,000/uL
  • Hemoglobin at least 6.2 mmol/L


  • Bilirubin no greater than 1.8 mg/dL
  • SGPT no greater than 96 u/L
  • SGOT no greater than 90 u/L
  • LDH no greater than 600


  • BUN no greater than 42 mg/dL
  • Creatinine no greater than 3.39 mg/dL


  • No cardiovascular risks (e.g., history of angina pectoris) unless controlled by medical or surgical therapy
  • No known history of thromboembolic disease


  • Comprehend and understand English language
  • No other prior malignancy within the past 5 years except treated squamous or basal cell skin cancer or superficial bladder carcinoma


Biologic therapy:

  • Not specified


  • At least a 4 week washout period is required if prior antineoplastic or cytotoxic chemotherapy has been used

Endocrine therapy:

  • At least a 4 week washout period is required if prior estrogens, antiandrogens (e.g., flutamide or bicalutamide), progestational agents, or corticosteroids have been used
  • No concurrent herbal medications with known hormonal ingredients (i.e., phytoestrogens)


  • Not specified


  • See Disease Characteristics


  • At least a 4 week washout period is required if prior clonidine or monoamine oxidase inhibitors have been used

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005623

United States, New York
Barr Laboratories, Incorporated
Pomona, New York, United States, 10970-0519
Sponsors and Collaborators
Barr Laboratories
Study Chair: Ronald W. Lewis, MD MBCCOP - Medical College of Georgia Cancer Center

ClinicalTrials.gov Identifier: NCT00005623     History of Changes
Other Study ID Numbers: CDR0000067765
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: March 26, 2013
Last Verified: December 2003

Keywords provided by National Cancer Institute (NCI):
stage IV prostate cancer
recurrent prostate cancer
hot flashes

Additional relevant MeSH terms:
Prostatic Neoplasms
Hot Flashes
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Signs and Symptoms
Cyproterone Acetate
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents
Contraceptive Agents, Male
Contraceptive Agents
Reproductive Control Agents